Even before Roche's offer to buy Genetech (NYSE:DNA) earlier this week, the biotechnology industry had performed well, especially since early June when the S&P 500 began a month-and-a-half long 11% decline.

Biotechnology exchange-traded funds (ETFs) like the SPDR S&P Biotech (AMEX:XBI), First Trust AMEX Biotechnology Index (AMEX:FBT), and Biotech HOLDRS (AMEX:BBH) have performed like a non-correlated asset group immune to the dreads of the overall market. Before choosing the fund with the hot hand of the day, it's important for investors to note how the composition of a fund can relate to its short term and long term performance results. In this article we'll explore the three biotech ETFs mentioned above, to show that what looks good today, may not be nearly as attractive a year from now. (For everything you need to know about this investment product, check out our Exchange-Traded Funds Feature.)

Near and Far
Since the beginning of the year:

  • Biotech HOLDRS (BBH) is up just over 18%.
  • The SPDR S&P Biotech (XBI) fund is up only 8%.
  • First Trust AMEX Biotechnology Index (FTB) is barely out of negative territory.

If we expand our time horizon out to three years, we find a different story:

  • BBH is just barely in positive territory.
  • XBI returned 46%.
  • FTB returned 24%.

What's Got Into BBH?
BBH is a more focused fund than the other ETFs mentioned with 60% of its holdings split between leading cancer drug maker Genetech and infectious disease fighter Gilead Sciences (Nasdaq:GILD). BBH has had a volatile three-year period only recently surpassing returns above those offered by the S&P 500. If you're bent on adding BBH to your portfolio you should also consider adding additional diversification in this space.

Best Bet - XBI's Diversity
XBI almost evenly allocates funds to its 24 biotech positions. Its top three holdings cancer drug maker Celgene (Nasdaq:CELG), cancer patient treatment provider ImClone Systems (Nasdaq:IMCL), and oral anticancer drug maker Onyx Pharmaceuticals (Nasdaq:ONXX) are popular among most of the Biotech ETFs, but XBI's even allocation sets it apart. Other well performing holdings year to date include Genetech and infectious disease fighter Vertex Pharmaceuticals (Nasdaq:VRTX). Be advised that the fund does have a relatively high turnover at rate 74%. (To better understand ETF holdings, read An Inside Look At ETF Construction.)

Runner Up - FTB
FBT is barely in positive territory since the beginning of the year but its investments in Vertex Pharmaceuticals, genetic variation decoder Illumnia (in route to personalized drug treatment), Genetech and Celegene have recently helped lift the fund out of negative territory since the beginning of the year. FBT holds only 20 stocks, but it also has a much lower turnover ratio of 11% and its investments are more evenly divided than the BBH fund.

Parting Thoughts
The list of diseases and aliments in need of a cure is long, giving biotechnology a prominent position in the minds of investors. Diversification is the key to building any successful portfolio. If you choose to concentrate in any one direction, try to find a complimentary investment to carry part of the load.

For further reading, see How To Use ETFs In Your Portfolio.

Related Articles
  1. Investing

    How to Ballast a Portfolio with Bonds

    If January and early February performance is any guide, there’s a new normal in financial markets today: Heightened volatility.
  2. Stock Analysis

    Performance Review: Emerging Markets Equities in 2015

    Find out why emerging markets struggled in 2015 and why a half-decade long trend of poor returns is proving optimistic growth investors wrong.
  3. Investing News

    Today's Sell-off: Are We in a Margin Liquidation?

    If we're in market liquidation, is it good news or bad news? That party depends on your timeframe.
  4. Investing News

    Bank Stocks: Time to Buy or Avoid? (WFC, JPM, C)

    Bank stocks have been pounded. Is this the right time to buy or should they be avoided?
  5. Stock Analysis

    Why the Bullish Are Turning Bearish

    Banks are reducing their targets for the S&P 500 for 2016. Here's why.
  6. Stock Analysis

    How to Find Quality Stocks Amid the Wreckage

    Finding companies with good earnings and hitting on all cylinders in this environment, although possible, is not easy.
  7. Chart Advisor

    How Are You Trading The Breakdown In Growth Stocks? (VOOG, IWF)

    Based on the charts of these two ETFs, bearish traders will start turning their attention to growth stocks.
  8. Mutual Funds & ETFs

    Pimco’s Top Funds for Retirement Income

    Once you're living off the money you've saved for retirement, is it invested in the right assets? Here are some from PIMCO that may be good options.
  9. Chart Advisor

    Watch This ETF For Signs Of A Reversal (BCX)

    Trying to determine if the commodity markets are ready for a bounce? Take a look at the analysis of this ETF to find out if now is the time to buy.
  10. Investing News

    What You Can Learn from Carl Icahn's Mistakes

    Carl Icahn has been a stellar performer in the investment world for decades, but following his lead these days could be dangerous.
  1. Should mutual funds be subject to more regulation?

    Mutual funds, when compared to other types of pooled investments such as hedge funds, have very strict regulations. In fact, ... Read Full Answer >>
  2. Do ETFs pay capital gains?

    Exchange-traded funds (ETFs) can generate capital gains that are transferred to shareholders, typically once a year, triggering ... Read Full Answer >>
  3. How do real estate hedge funds work?

    A hedge fund is a type of investment vehicle and business structure that aggregates capital from multiple investors and invests ... Read Full Answer >>
  4. Are Vanguard ETFs commission-free?

    While some Vanguard exchange-traded funds (ETFs) are available commission-free from third-party brokers, a large portion ... Read Full Answer >>
  5. Do Vanguard ETFs require a minimum investment?

    Vanguard completely waives any U.S. dollar minimum amounts to buy its exchange-traded funds (ETFs), and the minimum ETF investment ... Read Full Answer >>
  6. Can mutual fund expense ratios be negative?

    Mutual fund expense ratios cannot be negative. An expense ratio is the sum total of all fees charged by an asset management ... Read Full Answer >>
Trading Center